- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00478725
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects With Solid Tumor Malignancies
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Subject must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up. Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
- Has histologically or cytologically confirmed advanced solid tumor malignancy.
- For Part A: Males, age: 30 years or greater.
- For Part B: Males or Females, age: 18 years or greater.
- For Part A or B, males that meet the following criteria.
A male subject with a female partner of childbearing potential is eligible to enter and participate in this study if he:
- Agrees to use double-barrier contraception (condom with spermicidal jelly, foam, suppository or film, or a condom and his partner uses a diaphragm with spermicide), OR
- Agrees to complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the clinical trial, and for at least 21 days after the last dose of investigational product.
- For Part B, females that meet the following criteria:
A female subject is eligible to enter and participate in this study if she is of:
Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:
- A hysterectomy
- A bilateral oophorectomy (ovariectomy)
- A bilateral tubal ligation
- Is post-menopausal (total cessation of menses for >/ 1 year), OR
Childbearing potential and has a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
- An intrauterine device (IUD) with a documented failure rate of less than 1% per year.
- Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
- Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the clinical trial, and for at least 21 days after the last dose of investigational product.
- Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).
- Note: Oral contraceptives are not considered reliable due to potential drug-drug interaction.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Body weight >/ 50 kg.
- Adequate organ systems function as defined in Table 1.
- Ability to swallow and retain oral medication.
Exclusion criteria:
- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to beginning study treatment. Screening with CNS imaging studies (CT scan or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases.
- Clinically significant gastrointestinal (GI) abnormalities including, but not limited to: malabsorption syndrome, history of resection of the stomach or small bowel, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis or other conditions that increase the risk for perforation, history of abdominal fistula, GI perforation or intra-abdominal abscess within 4 weeks prior to beginning study treatment.
- Presence of uncontrolled infection.
- Corrected QT interval (QTc) > 480 msec.
- History of any one or more of the following cardiovascular conditions within the past 6 months: congestive heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina OR symptomatic peripheral vascular disease.
- Has poorly controlled hypertension (systolic blood pressure [SBP] >/ 140 mmHg, or diastolic blood pressure [DBP] >/ 90 mmHg).
- Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on 2 occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90 mmHg in order for a subject to be eligible for the study.
- History of cerebrovascular accident or pulmonary embolism within the past 6 months.
- History of untreated deep venous thrombosis (DVT) within the past 6 months.
- Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible.
- Prior major surgery or trauma within the past 28 days or presence of any wound, fracture or ulcer which is not fully healed.
- Evidence of active bleeding, bleeding diathesis or hemoptysis within 6 weeks prior to study treatment.
- Use of prohibited medications within the timeframes specified in Section 9.2, Prohibited Medications of the protocol.
- Use of an investigational agent, including an investigational anti-cancer agent within 28 days or 5 half-lives, whichever is longer, preceding the first dose of pazopanib.
- Treatment with any cancer therapy (including chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery or tumor embolization) within 14 days prior to the first dose of pazopanib.
- Note: Current treatment with leuprolide is permitted.
- Any ongoing potentially reversible toxicity from prior anti-cancer therapy that is > Grade 1 or any toxicity from prior anti-cancer therapy that is progressing in severity.
- Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study, including any condition that could interfere with the accurate assessment and recovery of [14C].
- History or presence of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Part A
Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
|
oral, 800 mg
Outros nomes:
oral, 400 mg radiolabeled
Outros nomes:
|
Experimental: Part B
characterize the pharmacokinetics of a single IV dose of GW786034
|
oral, 800 mg
Outros nomes:
IV, 5 mg
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Part A: excretion of radioactivity
Prazo: over 168 hrs
|
over 168 hrs
|
Part B: Plasma pazopanib, clearance (CL) and AUC(0-t), AUC(0-8),Cmax and half-life (t1/2) pazopanib and pazopanib metabolites (GSK 1268992, GSK1268997, GSK1071306 and GW700201)
Prazo: over 48 hrs
|
over 48 hrs
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Part A: Blood and plasma total radioactivity AUC(0-t), AUC(0-8),Cmax and t1/2
Prazo: over 168 hrs.
|
over 168 hrs.
|
Part B: Safety parameters
Prazo: over 48 hrs.
|
over 48 hrs.
|
Blood and plasma total radioactivity AUC(0-t), AUC(0-∞), Cmax and t1/2 following oral administration of 400 mg of [14C]-pazopanib containing approximately 70 µCi of radioactivity.
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Samples (for use in a separate study) to characterize and quantify metabolites of pazopanib in plasma, urine and feces.
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Blood:plasma ratio of total drug-related material (radioactivity).
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Plasma pazopanib AUC(0-t), AUC(0-∞), Cmax, tmax following oral administration of 400 mg of [14C]-pazopanib containing 70 µCi of radioactivity.
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Safety parameters: adverse events (AEs), vital signs, electrocardiograms (ECGs) and clinical laboratory assessments.
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Plasma pazopanib AUC(0-24), Cmax, tmax following oral administration of 800 mg pazopanib
Prazo: on Day 15 of Cycle 1.
|
on Day 15 of Cycle 1.
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- VEG10004
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Carcinoma de Células Renais
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillConcluídoDoenças Renais Crônicas | Doença Renal Crônica Estágio 5 | Doença Renal Crônica estágio 4 | Doença Renal Pediátrica | Doença Renal Crônica estágio 3 | Doença Renal Crônica Estágio V | Doença Renal Crônica, Estágio IV (Grave) | Doença Renal Crônica Estágio 2 | Doença Renal Crônica, Estágio IEstados Unidos
-
Novartis PharmaceuticalsConcluídoHemodiálise | Terapia Renal Substitutiva | Doença Renal em Estágio Terminal (ESRD) | Transplante Renal | Doença Renal Crônica (DRC)Alemanha, Estados Unidos, Bélgica, Itália, Espanha, Croácia, Taiwan, Austrália, Áustria, Grécia, Republica da Coréia, Líbano, Tcheca, Israel, Holanda, Eslovênia, Suíça, Tailândia, Noruega, Peru, Suécia, Argentina, Brasil, Japão, Sérvia, Federação... e mais
-
University Hospital, BordeauxMinistry of Health, FranceConcluídoTransplante Renal | Doença Renal Crônica em Estágio Terminal | Insuficiência Renal Aguda GraveFrança
-
A.C. AbrahamsConcluídoDoença renal em estágio final | Doença Renal Crônica | Doença renal terminal | Insuficiência Renal CrônicaHolanda
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and Kidney... e outros colaboradoresRecrutamentoDoenças Renais Crônicas | Insuficiência renal aguda | Lesão Renal Aguda | Insuficiência Renal Aguda | Insuficiência Renal Crônica | Insuficiência Renal Aguda | Insuficiência Renal Aguda | Insuficiência Renal Aguda | Insuficiência Renal Aguda | Insuficiência Renal Aguda | Insuficiência Renal Crônica | Doenças Renais... e outras condiçõesEstados Unidos
-
Angiodynamics, Inc.RescindidoDoença Renal Crônica | Lesão Renal Aguda | Insuficiência renal aguda | Insuficiência Renal Induzida por Contraste CrônicoEstados Unidos
-
National Taiwan University HospitalConcluídoDoença Renal Crônica estágio 4 | Doença Renal Crônica estágio 3 | Doença Renal Crônica Estágio 2 | Doença Renal Crônica Estágio 1Taiwan
-
University of CologneConcluídoInsuficiência Renal Crônica/Doença Renal | Lesão Renal Aguda Induzida por Meio de ContrasteAlemanha
-
Renibus Therapeutics, Inc.ConcluídoInsuficiência Renal AgudaEstados Unidos
-
European Society of Intensive Care MedicineConcluídoLesão Renal Aguda | Terapia Renal Substitutiva | Doença Renal Crônica em Estágio FinalBélgica
Ensaios clínicos em GW786034, oral
-
Case Comprehensive Cancer CenterConcluídoCarcinoma de Células Renais de Células Claras | Câncer de Células Renais Estágio III | Câncer de Células Renais Estágio I | Câncer de Células Renais Estágio IIEstados Unidos
-
National Cancer Institute (NCI)RetiradoSarcoma | Osteossarcoma | Tumor cerebral | Neuroblastoma | Tumor de WilmsEstados Unidos
-
Illinois CancerCare, P.C.RescindidoCâncer de Pulmão de Células Não PequenasEstados Unidos
-
GlaxoSmithKlineConcluídoCancro do ovário | Câncer de Trompa de Falópio | Câncer Peritoneal | Neoplasias OvarianasEstados Unidos, Austrália, Cingapura
-
Washington University School of MedicineNovartisRescindidoCâncer de Pulmão de Células Não Pequenas | Câncer de Pulmão de Células Não Pequenas | Carcinoma pulmonar de células não pequenasEstados Unidos
-
GlaxoSmithKlineConcluídoCarcinoma de Células RenaisEstados Unidos
-
GlaxoSmithKlineConcluídoSarcoma de Tecidos MolesBélgica, Holanda, Reino Unido, França, Hungria
-
Illinois CancerCare, P.C.RescindidoCâncer de próstataEstados Unidos
-
Novartis PharmaceuticalsChildren's Oncology GroupConcluídoTumores SólidosEstados Unidos, Canadá, Hungria, Espanha, França, Eslováquia, Tcheca
-
National Cancer Institute (NCI)ConcluídoNeoplasias | LinfomaEstados Unidos